肿瘤细胞治疗研究
英文原题：Dendritic cells in hematologic malignancies: a brief review of immunoregulation to new perspectives.
Dendritic cells in hematologic malignancies: a brief review of immunoregulation to new perspectives.
树突状细胞（DCs）是免疫系统的重要哨兵，在激活初始T细胞对抗白血病细胞中发挥关键作用。
树突状细胞（DC）是免疫系统的重要哨兵，在激活初始T细胞对抗白血病细胞中发挥关键作用。它们具有免疫调节功能，既能促进免疫应答，同时又能调节免疫耐受以避免过度反应。浆细胞样树突状细胞（pDC）肿瘤是一组复杂的疾病，在各亚型中，伴有pDC皮肤病变的急性髓系白血病（AML-pDC）尤为突出。在此背景下，pDC可通过抑制或促进免疫应答发挥免疫调节作用，并作为肿瘤祖细胞，因为在某些情况下，它们可与肿瘤微环境协作，促进免疫逃逸和增殖。然而，pDC在AML中的临床意义尚未完全明确。研究表明，pDC与白血病微环境的相互作用可能通过损害免疫系统控制肿瘤细胞的能力而促进疾病进展。理解DC在肿瘤中的作用至关重要，因为它为寻求创新治疗策略进展的新研究提供了重要见解，例如树突状细胞疫苗。这些疫苗具有前景，毒性低，且有潜力改善AML患者的预后，刺激有效的免疫应答。
Dendritic cells (DCs) are essential immune system sentinels, playing a key role in activating naïve T cells against leukemic cells. They have an immunomodulatory function, promoting an immune response and, at the same time, regulating immune tolerance to avoid excessive reactions. Plasmacytoid dendritic cell (pDC) neoplasms are a complex group of disorders, and among the subtypes, acute myeloid leukemia (AML) with pDC dermatosis (AML-pDC) stands out. In this context, pDCs can play an immunomodulatory role by inhibiting or promoting immune responses and acting as tumor progenitors since, in some cases, they can collaborate with the tumor microenvironment, favoring immune evasion and proliferation. However, the clinical significance of pDC in AML is not fully understood. Studies suggest that the interaction of pDCs with the leukemic microenvironment may contribute to disease progression by impairing the immune system's ability to control tumor cells. Understanding the role of DCs in neoplasia is crucial, as it provides important insights for new studies seeking advances in innovative therapeutic strategies, such as dendritic cell vaccines. These vaccines are promising, with low toxicity and the potential to improve the prognosis of individuals affected by AML, stimulating an effective immune response.
MEMBER ACCOUNT
登录成功会直接打开下一页。
